Page 58 - Haematologica - Vol. 105 n. 6 - June 2020

A. Bazarbachi et al.
leukemia in first remission: a retrospective study from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer. 2019;126 (5):1004-1015.
110.Versluis J, Labopin M, Ruggeri A, et al. Alternative donors for allogeneic hematopoietic stem cell transplantation in poor-risk AML in CR1. Blood Adv. 2017;1(7):477-485.
111. Kharfan-Dabaja MA, Labopin M, Polge E, et al. Association of second allogeneic hematopoietic cell transplant vs donor lym- phocyte infusion with overall survival in patients with acute myeloid leukemia relapse. JAMA Oncol. 2018;4(9):1245-1253.
112.Levis MJ, Chen Y-B, Hamadani M, et al. FLT3 inhibitor maintenance after allogeneic transplantation: is a placebo-controlled, ran- domized trial ethical? J Clin Oncol. 2019; 37(19):1604-1607.
113.Stone RM, Mandrekar SJ, Sanford BL, et al. The addition of midostaurin to standard chemotherapy decreases cumulative inci- dence of relapse (CIR) in the international prospective randomized, placebo-con- trolled, double-blind trial (CALGB 10603 /
RATIFY [Alliance]) for newly diagnosed acute myeloid leukemia (AML) Patients with FLT3 mutations. Blood. 2017;130 (Suppl 1):2580.
114.Maziarz RTT, Patnaik MM, Scott BL, et al. Radius: a phase 2 randomized trial investi- gating standard of care ± midostaurin after allogeneic stem cell transplant in FLT3-ITD- mutated AML. Blood. 2018;132(Suppl 1):662.
115.Schlenk RF, Weber D, Fiedler W, et al. Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood. 2019;133(8):840-851.
116. Antar A, Kharfan-Dabaja MA, Mahfouz R, Bazarbachi A. Sorafenib maintenance appears safe and improves clinical outcomes in FLT3-ITD acute myeloid leukemia after allogeneic hematopoietic cell transplanta- tion. Clin Lymphoma Myeloma Leuk. 2015;15(5):298-302.
117. Tschan-Plessl A, Halter JP, Heim D, Medinger M, Passweg JR, Gerull S. Synergistic effect of sorafenib and cGvHD in patients with high-risk FLT3-ITD+AML allows long-term disease control after allo-
geneic transplantation. Ann Hematol.
2015;94(11):1899-1905.
118. Yokoyama H, Lundqvist A, Su S, Childs R.
Toxic effects of sorafenib when given early after allogeneic hematopoietic stem cell transplantation. Blood. 2010;116(15):2858- 2859.
119. Mathew NR, Baumgartner F, Braun L, et al. Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells. Nat Med. 2018;24(3):282-291.
120. Levis MJ, Hamadani M, Logan B, et al. A phase 3, trial of gilteritinib, as maintenance therapy after allogeneic hematopoietic stem cell transplantation in patients with FLT3- ITD+ AML. J Clin Oncol. 2018;36 (15_Suppl):TPS7075.
121. Canaani J. Management of AML Beyond “3+ 7” in 2019. Clin Hematol Int. 2019;1(1): 10-18.
122.Culos K, Byrne M. Salvage therapy after allogeneic hematopoietic cell transplanta- tion: targeted and low-intensity treatment options in myelodysplastic syndrome and acute myeloid leukemia. Clin Hematol Int. 2019;1(2):94-100.
1516
haematologica | 2020; 105(6)